Ventripoint Diagnostics Ltd (VPTDF) 0.1049 $VPTDF
Ventripoint Announces New Director and Provides Corporate Update
Marketwired - Wed Nov 04, 7:57AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation"
(TSX VENTURE: VPT) announces that Dave Willis has joined the Board of Directors of the Corporation. Mr. Willis is an expert in the development and international sales of ultrasound equipment. Until recently, he was Vice President Competitive Strategy and Product Innovation at SonoSite-Fujifilm Ultrasound, where he was responsible for design input, launch and global training of 4 major product releases. He also served as Vice President of Sales and Marketing the Americas for Ultrasonix Medical Corp, where he managed sales forces in Canada, U.S.A, and South America.
VPT.VN: 0.150 (-0.010)
IIROC Trade Resumption - VentriPoint Diagnostics Ltd.
Newsfile Corp - Fri Oct 23, 8:31AM CDT
Trading resumes in:
Ventripoint Corporate Update
Marketwire Canada - Fri Oct 23, 8:24AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE:VPT) announces that subsequent to the departure of Mr. Jim Bodtke, the Board of Directors of the Company has accepted the resignations of Jeff Jellum, Director of Operations and Huy Le, Regional Account Manager.
VPT.VN: 0.150 (-0.010)
IIROC Trade Halt - VentriPoint Diagnostics Ltd.
Newsfile Corp - Wed Oct 21, 10:36AM CDT
The following issues have been halted by IIROC:
Ventripoint Announces Results of Annual Shareholders' Meeting and Engagement of Investor Relations Firm
Marketwired - Thu Oct 15, 6:32AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE: VPT) announces that at its Annual General Meeting on October 13, 2015 the shareholders elected Dr. George Adams, Mr. Danny Dalla-Longa, Dr. Alan Rabinowitz and Mr. Treuman Katz as Directors of the Company. They further approved the Incentive Stock Option plan and gave authority to the Board of Directors to undertake a share consolidation if it deems the consolidation is in the best interests of Ventripoint. BDO was appointed as auditors of the Company for the next year.
VPT.VN: 0.150 (-0.010)
Ventripoint Announces Development of New VMS(TM) Products and Enhanced Capabilities as Featured at ASE 2015
Marketwired - Thu Jun 25, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that a new platform design of the VMS(TM) workstation will be made available to select markets with complete availability expected in the 4th quarter of 2015. The new platform, branded VMS-Plus(TM), was the Company's featured product at the American Society of Echocardiography Scientific Session (ASE 2015) held in Boston last week.
VPT.VN: 0.150 (-0.010)
Ventripoint Receives Marketing Clearance from the FDA to Expand the Use of the VMS Heart Analysis System
Marketwired - Tue May 26, 7:31AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has received Marketing Clearance from the U.S. Food & Drug Administration ("FDA" for the expanded Indications for Use of its VMS(TM) product which states; "The VMS system is indicated for use where RV (right ventricle) volumes and ejection fractions are warranted or desired".
VPT.VN: 0.150 (-0.010)
Latest Clinical Study Finds Ventripoint VMS(TM) Offers Consistent and Accurate Results Regardless of Examiner
Marketwired - Mon Apr 27, 7:54AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that a group led by Dr. Daniel Knight in London, United Kingdom, has demonstrated further the accuracy of Ventripoint's VMS(TM) heart analysis system.
VPT.VN: 0.150 (-0.010)
Ventripoint Announces Response to Interactive Review for Recent 510(k) Submission to FDA
Marketwired - Wed Apr 08, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has completed the first round of review concerning the most recent 510(k) submission to the U.S. Food & Drug Administration ("FDA". On March 26th, 2015, Ventripoint received a request for additional information via Interactive Review. The Company responded promptly and delivered the requested information to the FDA for evaluation.
VPT.VN: 0.150 (-0.010)
Ventripoint Announces Distribution Partner for Military and VA Medical Centers
Marketwired - Mon Mar 30, 7:34AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation" (TSX VENTURE: VPT) is pleased to announce that is has appointed PYP Enterprises LLC (PYP) to be the exclusive distributor to the US military hospitals including the VA hospitals.
VPT.VN: 0.150 (-0.010)
Ventripoint Announces New Director and Provides Corporate Update
Marketwired - Wed Nov 04, 7:57AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation"
(TSX VENTURE: VPT) announces that Dave Willis has joined the Board of Directors of the Corporation. Mr. Willis is an expert in the development and international sales of ultrasound equipment. Until recently, he was Vice President Competitive Strategy and Product Innovation at SonoSite-Fujifilm Ultrasound, where he was responsible for design input, launch and global training of 4 major product releases. He also served as Vice President of Sales and Marketing the Americas for Ultrasonix Medical Corp, where he managed sales forces in Canada, U.S.A, and South America. VPT.VN: 0.150 (-0.010)
IIROC Trade Resumption - VentriPoint Diagnostics Ltd.
Newsfile Corp - Fri Oct 23, 8:31AM CDT
Trading resumes in:
Ventripoint Corporate Update
Marketwire Canada - Fri Oct 23, 8:24AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"
(TSX VENTURE:VPT) announces that subsequent to the departure of Mr. Jim Bodtke, the Board of Directors of the Company has accepted the resignations of Jeff Jellum, Director of Operations and Huy Le, Regional Account Manager. VPT.VN: 0.150 (-0.010)
IIROC Trade Halt - VentriPoint Diagnostics Ltd.
Newsfile Corp - Wed Oct 21, 10:36AM CDT
The following issues have been halted by IIROC:
Ventripoint Announces Results of Annual Shareholders' Meeting and Engagement of Investor Relations Firm
Marketwired - Thu Oct 15, 6:32AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"
(TSX VENTURE: VPT) announces that at its Annual General Meeting on October 13, 2015 the shareholders elected Dr. George Adams, Mr. Danny Dalla-Longa, Dr. Alan Rabinowitz and Mr. Treuman Katz as Directors of the Company. They further approved the Incentive Stock Option plan and gave authority to the Board of Directors to undertake a share consolidation if it deems the consolidation is in the best interests of Ventripoint. BDO was appointed as auditors of the Company for the next year. VPT.VN: 0.150 (-0.010)
Ventripoint Announces Development of New VMS(TM) Products and Enhanced Capabilities as Featured at ASE 2015
Marketwired - Thu Jun 25, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that a new platform design of the VMS(TM) workstation will be made available to select markets with complete availability expected in the 4th quarter of 2015. The new platform, branded VMS-Plus(TM), was the Company's featured product at the American Society of Echocardiography Scientific Session (ASE 2015) held in Boston last week. VPT.VN: 0.150 (-0.010)
Ventripoint Receives Marketing Clearance from the FDA to Expand the Use of the VMS Heart Analysis System
Marketwired - Tue May 26, 7:31AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has received Marketing Clearance from the U.S. Food & Drug Administration ("FDA" for the expanded Indications for Use of its VMS(TM) product which states; "The VMS system is indicated for use where RV (right ventricle) volumes and ejection fractions are warranted or desired". VPT.VN: 0.150 (-0.010)
Latest Clinical Study Finds Ventripoint VMS(TM) Offers Consistent and Accurate Results Regardless of Examiner
Marketwired - Mon Apr 27, 7:54AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that a group led by Dr. Daniel Knight in London, United Kingdom, has demonstrated further the accuracy of Ventripoint's VMS(TM) heart analysis system. VPT.VN: 0.150 (-0.010)
Ventripoint Announces Response to Interactive Review for Recent 510(k) Submission to FDA
Marketwired - Wed Apr 08, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has completed the first round of review concerning the most recent 510(k) submission to the U.S. Food & Drug Administration ("FDA". On March 26th, 2015, Ventripoint received a request for additional information via Interactive Review. The Company responded promptly and delivered the requested information to the FDA for evaluation. VPT.VN: 0.150 (-0.010)
Ventripoint Announces Distribution Partner for Military and VA Medical Centers
Marketwired - Mon Mar 30, 7:34AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation"
(TSX VENTURE: VPT) is pleased to announce that is has appointed PYP Enterprises LLC (PYP) to be the exclusive distributor to the US military hospitals including the VA hospitals. VPT.VN: 0.150 (-0.010)
